Contract of Adhesion

A contract of adhesion is a type of insurance contract in which one party, typically the insurer, has significantly more bargaining power than the other party, typically the policyholder. This type of contract is considered to be one-sided, as the policyholder typically has little to no input in negotiating the terms and conditions of the contract.

Some key features of a contract of adhesion include:

  • Non-negotiable terms: In a contract of adhesion, the terms and conditions of the contract are typically non-negotiable and presented to the policyholder on a take-it-or-leave-it basis.

  • Standardized language: The language used in a contract of adhesion is typically standardized and may be difficult for the average person to understand without legal assistance.

  • Imbalanced bargaining power: In a contract of adhesion, the insurer typically has significantly more bargaining power than the policyholder, as the policyholder may not have the ability to negotiate the terms or conditions of the contract.

  • Legal remedies: In the event of a dispute, the policyholder may have limited legal remedies available to them due to the nature of the contract.

For example, when applying for a homeowner's insurance policy, the policyholder may be presented with a standard contract of adhesion that outlines the terms and conditions of the policy. These terms may include the coverage limits, deductibles, and exclusions, and may not be negotiable by the policyholder. If the policyholder has concerns or questions about the terms of the contract, they may need to seek legal assistance to fully understand the implications of the agreement.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.